Drug Type AAV based gene therapy |
Synonyms SPVN30 |
Target |
Action modulators |
Mechanism GIRK modulators(GIRK channel modulators), NXNL1 modulators(nucleoredoxin like 1 modulators), RdCVFL modulators(Rod derived Cone Viability Factor Long form modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Retinitis Pigmentosa | Preclinical | France | 27 Mar 2022 |